GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment

Du, Youwei; Zhang, Qian; Jing, Lijia; liang, Xiaolong; Chi, Chongwei; Li, Yaqian; Yang, Xin; Dai, Zhifei; Tian, Jie

doi:10.2147/ott.s82029

Cited by 3 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the ES-NPs produced and used in our study may improve the stability and release of ES in a sustained manner. Accordingly, we observed that ES encapsulated into NPs exhibited a better antiangiogenic effect than free ES in vitro , which was consistent with work by Du et al ( 2015 ). Furthermore, CS could promote the contact between the protein drug and biomembranes (Wang et al, 2011 ), thereby improving the availability of the protein drug, which may also contribute to the results we have obtained.…”

Section: Discussionsupporting

confidence: 93%

“…Methods, such as the preparation of PEGylated ES (Tong et al, 2010 ), ES microsphere (Wu et al, 2009 ) and ES-loaded NPs have been used to try to overcome these shortcomings. Although ES-loaded PEG-PLGA (Hu & Zhang, 2010 ) and PLA (Du et al, 2015 ) NPs were reported previously, in this work, we have prepared new ES NPs, named ES-NPs, and evaluated their characteristics and antitumor effects.…”

Section: Discussionmentioning

confidence: 94%

“…It has been reported that CS NPs can protect the protein within the particle core (Amidi et al, 2010 ), avoiding degradation by enzymes and slowing filtration by the kidneys, thus increasing the protein retention in circulation. In previous studies, synthetic polymers such as PEG-PLGA (Hu & Zhang, 2010 ) and PLA (Du et al, 2015 ) were used to form long-acting NPs encapsulating ES. However, the preparation of these NPs required organic solvents to form w/o emulsions, which may adversely affect the stability of proteins.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model

Ding

Xie

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

The purpose of this study was to prepare ES-loaded chitosan nanoparticles (ES-NPs) and evaluate the antitumor effect of these particles on the Lewis lung cancer model. ES-NPs were prepared by a simple ionic cross-linking method. The characterization of the ES-NPs, including size distribution, zeta potential, loading efficiency and encapsulation efficiency (EE), was performed. An in vitro release test was also used to determine the release behavior of the ES-NPs. Cell viability and cell migration were assayed to detect the in vitro antiangiogenic effect of ES-NPs. In order to clarify the antitumor effect of ES-NPs in vivo, the Lewis lung cancer model was used. ES-NPs were successfully synthesized and shown to have a suitable size distribution and high EE. The nanoparticles were spherical and homogeneous in shape and exhibited an ideal releasing profile in vitro. Moreover, ES-NPs significantly inhibited the proliferation and migration of human umbilical vascular endothelial cells (HUVECs). The in vivo antiangiogenic activity was evaluated by ELISA and immunohistochemistry analyses, which revealed that ES-NPs had a stronger antiangiogenic effect for reinforced anticancer activity. Indeed, even the treatment cycle in which ES-NPs were injected every seven days, showed stronger antitumor effect than the free ES injected for 14 consecutive days. Our study confirmed that the CS nanoparticle is a feasible carrier for endostatin to be used in the treatment of lung cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model

Ding

Xie

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…4 ). Improved internalization capacity at shorter incubation times, being indicative of a specific interaction with the receptor of interest, has been previously reported for other targeted nanosystems decorated with transferrin 48 , folate 49 and antiangiogenic peptides 50 . Although additional experiments would be needed to perform a deep comprehension of the interaction between UroGm-SNs and GCC receptor, we can state that our formulation shows a better interaction with the targeted cells and that UroGm is playing a positive role.…”

Section: Resultssupporting

confidence: 60%

Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer

Bouzo

Lores

Jatal

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Colorectal cancer is the third most frequently diagnosed cancer malignancy and the second leading cause of cancer-related deaths worldwide. Therefore, it is of utmost importance to provide new therapeutic options that can improve survival. Sphingomyelin nanosystems (SNs) are a promising type of nanocarriers with potential for association of different types of drugs and, thus, for the development of combination treatments. In this work we propose the chemical modification of uroguanylin, a natural ligand for the Guanylyl Cyclase (GCC) receptor, expressed in metastatic colorectal cancer tumors, to favour its anchoring to SNs (UroGm-SNs). The anti-cancer drug etoposide (Etp) was additionally encapsulated for the development of a combination strategy (UroGm-Etp-SNs). Results from in vitro studies showed that UroGm-Etp-SNs can interact with colorectal cancer cells that express the GCC receptor and mediate an antiproliferative response, which is more remarkable for the drugs in combination. The potential of UroGm-Etp-SNs to treat metastatic colorectal cancer cells was complemented with an in vivo experiment in a xenograft mice model.

show abstract

“…The comparison of these agents showed that the tumor inhibitory effect of GEN is better than EPNPs and Endostar, because the GX1 simplified drug accumulation in the tumor sites, and also facilitates the monitoring of drug releasing in tumor regions. 99 Luo et al evaluated the antitumor activity of gold nano-shell particles of Endostar (G- Endostar) and indicated that enhance the inhibitory activity of Endostar. 97 Endostar easily degrades and equally distributes to all tissues.…”

Section: Clinical Application Challengesmentioning

confidence: 99%

The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering

Mohajeri¹,

Sanaei

Kiafar³

et al. 2017

Adv Pharm Bull

View full text Add to dashboard Cite

Angiogenesis plays an essential role in rapid growing and metastasis of the tumors. Inhibition of angiogenesis is a putative strategy for cancer therapy. Endostatin (Es) is an attractive anti-angiogenesis protein with some clinical application challenges including; short half-life, instability in serum and requirement to high dosage. Therefore, production of recombinant endostatin (rEs) is necessary in large scale. The production of rEs is difficult because of its structural properties and is high-cost. Therefore, this review focused on the different expression systems that involved in rEs production including; mammalian, baculovirus, yeast, and Escherichia coli (E. coli) expression systems. The evaluating of the results of different expression systems declared that none of the mentioned systems can be considered to be generally superior to the other. Meanwhile with considering the advantages and disadvantage of E. coli expression system compared with other systems beside the molecular properties of Es, E. coli expression system can be a preferred expression system for expressing of the Es in large scale. Also, the molecular bioengineering and sustained release formulations that lead to improving of its stability and bioactivity will be discussed. Point mutation (P125A) of Es, addition of RGD moiety or an additional zinc biding site to N-terminal of Es , fusing of Es to anti-HER2 IgG or heavy-chain of IgG, and finally loading of the endostar by PLGA and PEG- PLGA nanoparticles and gold nano-shell particles are the effective bioengineering methods to overcome to clinical changes of endostatin.

show abstract

GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment

Cited by 3 publications

References 29 publications

Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model

Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model

Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer

The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering

Contact Info

Product

Resources

About